Skye Bioscience received a formal notice from Nasdaq on May 13, 2026, regarding non-compliance with listing standards. The company's stockholders' equity was reported at $9,011,804 as of March 31, 2026, falling short of the $10,000,000 minimum required by Nasdaq Global Market Rule 5450(b)(1)(A). The notice does not immediately impact the trading of SKYE common stock. The company has until June 29, 2026, to submit a compliance plan to Nasdaq.